Glecirasib Shows Promise in Treating Patients with Advanced Lung Cancer Harboring KRAS G12C Mutations

Patients with KRASG12C mutated non-small cell lung cancer (NSCLC) who were treated with glecirasib, a KRASG12C-inhibitor, experienced promising outcomes according to new findings that were presented in the April 30, 2024 session of the American Society of Clinical Oncology (ASCO) Plenary Series. The KRASG12C mutation occurs in approximately 4.3% of NSCLC cases in China, and there are currently no approved targeted therapies for this type of mutation in China. This phase II single-arm study conducted across 43 sites in China provides new data on the effectiveness of glecirasib in patients who have progressed after standard treatment with chemotherapy and immunotherapy treatment. The study enrolled 119 participants with advanced stages of NSCLC who previously received platinum-based and immune checkpoint inhibitor therapies. The primary objective was overall response rate (ORR), with secondary objectives including duration of response (DOR), progression-free survival (PFS), and overall survival (OS).

Login Or Register To Read Full Story